Front-Line Combination Therapy of Sunitinib Malate Plus Chemotherapy With Leucovorin/5-Fluorouracil and Irinotecan (FOLFIRI) for Rectal Cancer Patients With Synchronous Non-Resectable Metastases: A Phase II Non Controlled Study (SUREMETS).

Trial Profile

Front-Line Combination Therapy of Sunitinib Malate Plus Chemotherapy With Leucovorin/5-Fluorouracil and Irinotecan (FOLFIRI) for Rectal Cancer Patients With Synchronous Non-Resectable Metastases: A Phase II Non Controlled Study (SUREMETS).

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2013

At a glance

  • Drugs Sunitinib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Cancer metastases; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms SUREMETS
  • Most Recent Events

    • 20 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top